Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.

Revenue
+1.57%
EPS
−75.4%
Free cash flow
+278.7%
Total debt
−14.7%

Quarter to September 2026, against a year earlier

61.20 3.14 +5.41%
Market cap
$8.9B
P/E
0.0×
Fwd P/E
−412×
Dividend yield
0.34%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
2.08 1.59 2.62 2.81
P/FCF ratio
105.01 72.24 77.21 36.64
P/Operating CF
31.12 77.21 (118.42) 83.54
P/B ratio
2.89 2.23 3.82 4.11
EV/Sales
2.54 2.03 3.09 3.26
EV/EBITDA
30.23 25.60 54.16 72.26
EV/FCF
128.07 92.45 91.03 42.55
Current Ratio
1.73 1.55 1.85 1.84
Net Debt/EBITDA
11.68 22.45 (224.64) 0.00
Debt/Equity
0.76 0.68 0.76 0.74
Earnings Yield
(0.32%) (0.66%) (1.16%) (1.56%)
Free Cash Flow Yield
0.95% 1.38% 1.30% 2.73%
Free Cash Flow per Share
1.37 0.31 (0.70) 0.63
Book value per Share
16.29 16.21 15.76 15.12
Free Cash Flow
207.20 47.00 (106.20) 96.70
EV/EBIT
127.88 150.97 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026